Contract Orientation & Kickoff Meeting for PREVENT Cancer Preclinical Drug Development Program: CGMP Pool

The NCI PREVENT Cancer Preclinical Drug Development Program (PREVENT) was initially launched in 2012 to provide extramural research community with structured research support resources for preclinical development of cancer preventive agents, including agent optimization, CGMP manufacturing and IND-enabling studies.

The PREVENT Program is a peer-reviewed research and development program and implements meritorious projects once approved by the management committee.

The PREVENT Preclinical Services for Biopharmaceutical Product Development and Manufacturing” (hereinafter referred to as PREVENT CGMP) IDIQ contractor will provide preclinical product development and CGMP manufacturing support for candidate agents that enter the PREVENT pipeline.

The PREVENT CGMP contract activities encompass four main technical task areas: (1) product development planning and evaluation; (2) analytical assay development and product characterization; (3) process development and related activities; and (4) CGMP manufacturing, related activities, and documentation.